[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

Официальное название

Imaging PARP Expression in Cholangiocarcinoma

Обзор

This phase II trial studies whether \[18F\]FTT can be used with positron emission tomography (PET)/computed tomography (CT) imaging to predict treatment response in patients scheduled to receive gemcitabine, cisplatin, and durvalumab (GCD) for newly diagnosed cholangiocarcinoma. PET/CT is an imaging technique that utilizes PET and CT in a single machine. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this trial, \[18F\]FTT, to make detailed, computerized pictures of areas inside the body where the tracer is used. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the patient's body. \[18F\]FTT targets and binds to poly (ADP-ribose) polymerase 1 (PARP1). Some cholangiocarcinoma tumor cells may express PARP1 which may make it easier to see them on PET/CT. Research has shown that tumor cells that express PARP1 may not respond well to GCD treatment. Researchers hope that by using \[18F\]FTT with PET/CT imaging they will be able to detect which patients have tumor cells that express PARP1, which may help predict treatment response in patients scheduled to receive GCD for newly diagnosed cholangiocarcinoma.

Подробное описание

OUTLINE:

Patients receive \[18F\]FTT intravenously (IV) and 60, 90, or 150 minutes later undergo PET/CT within 30 days prior to day 1 cycle 1 of GCD and 12 weeks after starting GCD in the absence of unacceptable toxicity. Patients also undergo CT and/or magnetic resonance imaging (MRI) throughout the study.

After completion of study intervention, patients are followed up at week 24 and then up to 6 months after completing GCD treatment.

Вмешательства

• Процедура Computed Tomography
  Undergo PET/CT and/or CT
• Лучевая терапия Fluorine F 18 Fluorthanatrace
  Given IV
• Процедура Magnetic Resonance Imaging
  Undergo MRI
• Процедура Positron Emission Tomography
  Undergo PET/CT

Первичные конечные точки

• Relationship between standardized uptake value maximum (SUVmax) and overall response rate [Срок оценки: At baseline and 24 weeks after starting gemcitabine, cisplatin, and durvalumab (GCD)]

Вторичные конечные точки (3)

• Relationship between standardized uptake value mean (SUVmean) and overall response rate [Срок оценки: At baseline and 24 weeks after starting GCD]
• Change in SUVmax and response [Срок оценки: Baseline to 12 weeks after starting GCD]
• Change in SUVmean and response [Срок оценки: Baseline to 12 weeks after starting GCD]

Критерии участия

Критерии включения

• Patient must have histologically confirmed cholangiocarcinoma
• Patient must be newly diagnosed and have not yet been treated
• Patient planned to receive GCD per standard-of-care
• Patient must have evaluable disease or at least one measurable lesion that can be assessed at baseline by CT (or MRI) per RECIST 1.1
• Age ≥ 18 years
• For women of childbearing potential, a negative serum pregnancy test is required within 7 days prior to \[18F\]FTT PET imaging
• Men and women of reproductive potential need to agree to employ acceptable forms of contraception throughout their participation in the study that meet requirements for GCD treatment per standard of care
• Patient is willing and able to comply with the protocol for the duration of the study including undergoing all study procedures
• Ability to understand and the willingness to sign a written informed consent document. Informed consent must be provided prior to any study specific procedures

Критерии исключения

• Pregnant or breastfeeding women
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Диагностика

Центры проведения

США · 1 центр

• Fred Hutch/University of Washington Cancer Consortium — Seattle

Идентификаторы

NCT: NCT07673341 · RG1126474 · NCI-2026-03509

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗